Prognostic value of the systemic immune-inflammation index in bladder cancer: an update evidence-based analysis.

ABSTRACT:

Background

Bladder cancer (BC) prognosis remains challenging to predict accurately with conventional tools. Systemic immune-inflammation index (SII) has emerged as a promising biomarker reflecting the tumor microenvironment. However, existing studies are limited by small sample sizes, heterogeneous designs, and inconsistent endpoints. This updated meta-analysis aims to comprehensively evaluate the association between high SII and key survival outcomes in BC patients.

Methods

We systematically searched PubMed, Embase, Web of Science, and Cochrane up to August 2025. Cohort studies reporting hazard ratios (HRs) for overall survival (OS), recurrence-free survival (RFS), progression-free survival (PFS), or cancer-specific survival (CSS) comparing high vs. low SII groups in histol

SUBMITTER: Bai J 

PROVIDER: S-EPMC12591970 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature